Company Overview of The Global Alliance for TB Drug Development
Key Executives for The Global Alliance for TB Drug Development
|Melvin K. Spigelman M.D.||43 Relationships||Chief Executive Officer, President and Director||67|
|Petro Terblanche||13 Relationships||President of Stakeholders Association and Director||--|
|Marshall Burke Ph.D.||No Relationships||Senior Vice President of External Affairs||--|
|Dean R. Haubrich Ph.D.||1 Relationships||Head of Project Management||--|
|Carl M. Mendel M.D., Ph.D.||No Relationships||Senior Vice President of Research and Development||61|
|View More Key Executives|
The Global Alliance for TB Drug Development Board Members*
|Name||Board Relationships||Primary Company||Age|
|Bruce L. A. Carter Ph.D.||200 Relationships||Enanta Pharmaceuticals, Inc.||73|
|Melvin K. Spigelman M.D.||43 Relationships||The Global Alliance for TB Drug Development||67|
|Petro Terblanche||13 Relationships||The Global Alliance for TB Drug Development||--|
|Mark Kessel J.D.||36 Relationships||Symphony Capital LLC||74|
|Anthony MBewu||9 Relationships||The Global Alliance for TB Drug Development||--|
The Global Alliance for TB Drug Development Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|There is no committee data available.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
INDUSTRY EXECUTIVE CHANGESThere is no Executive Change data available.
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.